Dadachanji Group establishes Kaisha Pharma with €45 million investment

Dadachanji Group has launched Kaisha Pharma, a specialised pharmaceutical manufacturing operation backed by an initial investment of €45 million. The new company will focus on producing high-precision injectable products including ampoules, vials, prefilled syringes and cartridges.

The facility is designed to cater to both Indian and global pharmaceutical and biotechnology companies seeking reliable contract manufacturing solutions. This positioning reflects India's expanding role as a supplier of advanced pharmaceutical manufacturing services to international markets.

The investment underscores growing interest among established business groups in strengthening India's pharmaceutical infrastructure, particularly in areas requiring specialised manufacturing capabilities. Kaisha Pharma's focus on injectable delivery systems addresses demand from the sector as companies increasingly require sophisticated packaging and delivery mechanisms for biologics and specialty drugs.

The venture represents Dadachanji Group's expansion into the contract manufacturing space, capitalising on the sector's growth prospects in India and across Asia. As regulatory standards for injectable products tighten globally, facilities meeting international quality benchmarks are becoming increasingly valuable to both domestic and multinational pharmaceutical firms.